サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1789370

凝固因子欠乏症市場：疾患の種類別、治療の種類別、剤形別、投与経路別、年齢層別、エンドユーザー別、地域別

Coagulation Factor Deficiency Market, By Disorder Type, By Treatment Type, By Dosage Form, By Route of Administration, By Age Group, By End User, By Geography

出版日
ページ情報
英文 135 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.02円
凝固因子欠乏症市場：疾患の種類別、治療の種類別、剤形別、投与経路別、年齢層別、エンドユーザー別、地域別
出版日: 2025年07月07日
発行: Coherent Market Insights
ページ情報: 英文 135 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

凝固因子欠乏症市場は、2025年には50億1,000万米ドルと推定され、2032年には89億米ドルに達すると予測され、2025年から2032年までの年間平均成長率（CAGR）は8.2%で成長する見込みです。

分析範囲 分析詳細
基準年 2024年 市場規模 (2025年) 50億1,000万米ドル
実績データ 2020～2024年 予測期間 2025～2032年
予測期間のCAGR (2025～2032年) 8.20% 予測金額 (2032年) 89億米ドル

世界の凝固因子欠乏症市場は、正常な止血に不可欠な特定の凝固因子の欠失または機能不全を特徴とする、まれではあるが生命を脅かす遺伝性出血性疾患に対応する、広範な血液学治療薬の中でも重要なセグメントです。凝固因子欠乏症には、血友病A（第VIII因子欠乏症）、血友病B（第IX因子欠乏症）、および第I、II、V、VII、X、XI、XIII因子を含む希少欠乏症があり、合わせて世界中で約40万人が罹患しています。

これらの疾患は、出血エピソードの長期化、自然出血、外科手術のリスクの増大によって現れ、因子補充療法、予防的治療、新たな遺伝子治療による生涯にわたる管理が必要となります。同市場は、技術の進歩と凝固カスケード機構の理解向上により、血漿由来の濃縮製剤から組換え因子製剤や半減期延長製剤へと大きく進化しています。医療従事者の意識の高まり、診断能力の向上、患者登録の改善、新興国市場における専門医療へのアクセスの拡大などが市場開拓に寄与しています。非因子療法、皮下製剤、遺伝子編集技術などの革新的なアプローチにより、治療環境は変貌を続けており、これらの慢性疾患に伴う経済的負担に対処しながら、患者の利便性の向上とQOLの改善を実現しています。

市場力学

世界の凝固因子欠乏症市場は、先進国市場および新興国市場において、相互に関連する複数の要因によって牽引される力強い成長ダイナミクスを示しています。主な市場促進要因としては、診断技術の向上や新生児スクリーニングプログラムの拡大による遺伝性出血性疾患の有病率の増加が挙げられ、これにより早期発見と治療開始が促進されています。バイオテクノロジーの技術的進歩は治療パラダイムに革命をもたらし、半減期が延長された遺伝子組換え因子の開発は注射回数を減らし、患者のコンプライアンスを向上させ、エミシズマブのような新規の非因子療法はインヒビター患者に代替治療の選択肢を提供しています。新興国を中心としたヘルスケア支出の増加と、啓発キャンペーンや患者支援活動の活発化が相まって、市場アクセシビリティが拡大し、先進的治療薬への需要が高まっています。規制上の優遇措置や迅速な承認パスウェイなど、希少疾患研究や希少疾病用医薬品の開発を支援する政府のイニシアチブは、市場の成長をさらに刺激します。しかし、濃縮因子製剤や先進治療薬にかかる法外なコストが市場の大きな抑制要因となっており、資源が乏しい環境でのアクセスが制限され、ヘルスケアシステムに大きな経済的負担を強いています。重症血友病A患者の約25～30%に中和抗体（インヒビター）が開発されているため、治療戦略が複雑化し、治療コストが増大しています。新興国市場におけるヘルスケア提供者の認知度の低さ、製品流通のための不十分なコールドチェーンインフラ、異なる市場間の複雑な規制がさらなる課題となっています。血漿由来製品のサプライチェーンの混乱や血漿不足は、市場の不安定性を生み出しています。とはいえ、潜在的な機能的治療法と長期的な費用対効果が期待できる遺伝子治療の開発が拡大することで、大きなビジネスチャンスが生まれます。個別化医療アプローチへの注目の高まり、遠隔患者モニタリングのための遠隔医療統合、アジア太平洋および中南米市場におけるヘルスケアインフラ投資の増加は、市場拡大の大きな可能性を示しています。

当レポートの主な特徴

  • 当レポートは、世界の凝固因子欠乏症市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模・CAGRを掲載しています。
  • また、各セグメントの潜在的な収益機会を明らかにし、この市場の魅力的な投資提案のマトリックスについて説明しています。
  • また、市場の促進要因・抑制要因や機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
  • 世界の凝固因子欠乏症市場における主要企業プロファイルを、企業概要、製品ポートフォリオ、主要なハイライト、財務実績、戦略などの以下のパラメータに基づいて掲載しています。
  • 当レポートの洞察を用いて、マーケティング担当者や企業の経営陣が、将来の製品発売・提携・市場拡大・マーケティング戦術に関する、十分な情報に基づいた意思決定を下すことができます。
  • 「世界の凝固因子欠乏症市場」レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者に対応しています。
  • 利害関係者は、世界の凝固因子欠乏症市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 分析目的と前提条件

  • 分析目的
  • 前提条件
  • 略語

第2章 市場の展望

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー

第3章 市場力学・規制・動向分析

  • 市場力学
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析
  • 主な発展
  • 規制シナリオ
  • 製品の発売/承認
  • PEST分析
  • PORTERの分析
  • 合併と買収のシナリオ
  • 業界動向

第4章 世界の凝固因子欠乏症市場、疾患の種類別（2020～2032年）

  • 血友病A（第VIII因子欠乏症）
  • 血友病B（第IX因子欠乏症）
  • 血友病C（第XI因子欠乏症）
  • フォン・ヴィレブランド病
  • 希少因子欠乏症

第5章 世界の凝固因子欠乏症市場、治療の種類別（2020～2032年）

  • 補充療法
  • 非置換療法
  • 遺伝子治療
  • その他（ホルモン療法）

第6章 世界の凝固因子欠乏症市場：剤形別（2020～2032年）

  • 再構成用凍結乾燥粉末
  • 注射/点滴用液体溶液
  • 経口製剤
  • 鼻スプレー
  • その他のウイルスベクター懸濁液

第7章 世界の凝固因子欠乏症市場：投与経路別（2020～2032年）

  • 静脈内
  • 皮下
  • 鼻腔内
  • オーラル

第8章 世界の凝固因子欠乏症市場：年齢層別（2020～2032年）

  • 小児
  • 成人

第9章 世界の凝固因子欠乏症市場：エンドユーザー別（2020～2032年）

  • 病院
  • 専門薬局
  • 血友病治療センター
  • 在宅医療
  • 専門クリニック
  • 外来手術センター（ASC）
  • その他（学術調査機関等）

第10章 世界の凝固因子欠乏症市場：地域別（2020～2032年）

  • 北米
      • 米国
      • カナダ
  • ラテンアメリカ
      • ブラジル
      • アルゼンチン
      • メキシコ
      • その他ラテンアメリカ
  • 欧州
      • ドイツ
      • 英国
      • スペイン
      • フランス
      • イタリア
      • ロシア
      • その他欧州
  • アジア太平洋
      • 中国
      • インド
      • 日本
      • オーストラリア
      • 韓国
      • ASEAN
      • その他アジア太平洋
  • 中東
      • GCC諸国
      • イスラエル
      • その他中東
  • アフリカ
      • 南アフリカ
      • 北アフリカ
      • 中央アフリカ

第11章 競合情勢

  • Baxter International Inc.
  • CSL Behring
  • Grifols S.A.
  • Takeda Pharmaceutical Company
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Bayer AG
  • Sobi（Swedish Orphan Biovitrum）
  • Biogen Inc.
  • Octapharma AG
  • Sanofi S.A.
  • Amgen Inc.
  • Genentech, Inc.
  • UCB S.A.

第12章 アナリストの提言

  • 「運命の輪」
  • アナリストの見解
  • Coherent Opportunity Map (COM)

第13章 参考文献と調査手法

  • 参考文献
  • 分析手法
  • Coherent Market Insightsについて
目次
Product Code: CMI8199

Coagulation Factor Deficiency Market is estimated to be valued at USD 5.01 Bn in 2025 and is expected to reach USD 8.90 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.2% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 5.01 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 8.20% 2032 Value Projection: USD 8.90 Bn

The global coagulation factor deficiency market represents a critical segment within the broader hematology therapeutics landscape, addressing rare but life-threatening inherited bleeding disorders characterized by the absence or dysfunction of specific clotting factors essential for normal hemostasis. Coagulation factor deficiencies encompass a spectrum of conditions including hemophilia A (Factor VIII deficiency), hemophilia B (Factor IX deficiency), and rarer deficiencies involving factors I, II, V, VII, X, XI, and XIII, collectively affecting approximately 400,000 individuals worldwide.

These disorders manifest through prolonged bleeding episodes, spontaneous hemorrhages, and increased surgical risks, necessitating lifelong management through factor replacement therapies, prophylactic treatments, and emerging gene therapies. The market has witnessed substantial evolution from plasma-derived concentrates to recombinant factors and extended half-life products, driven by technological advancements and improved understanding of coagulation cascade mechanisms. Rising awareness among healthcare professionals, enhanced diagnostic capabilities, improved patient registries, and expanding access to specialized care in developing regions contribute to market growth. The therapeutic landscape continues to transform with innovative approaches including non-factor therapies, subcutaneous formulations, and gene editing technologies, offering enhanced convenience and improved quality of life for patients while addressing the substantial economic burden associated with these chronic conditions.

Market Dynamics

The global coagulation factor deficiency market demonstrates robust growth dynamics driven by multiple interconnected factors that shape its trajectory across developed and emerging markets. Primary market drivers include the increasing prevalence of inherited bleeding disorders due to improved diagnostic techniques and expanded newborn screening programs, which enhance early detection and treatment initiation. Technological advancements in biotechnology have revolutionized treatment paradigms, with the development of extended half-life recombinant factors reducing injection frequency and improving patient compliance, while novel non-factor therapies like emicizumab provide alternative treatment options for patients with inhibitors. Rising healthcare expenditure, particularly in emerging economies, coupled with growing awareness campaigns and patient advocacy initiatives, expands market accessibility and drives demand for advanced therapeutics. Government initiatives supporting rare disease research and orphan drug development, including regulatory incentives and expedited approval pathways, further stimulate market growth. However, significant market restraints persist, primarily centered around the prohibitive cost of factor concentrates and advanced therapies, which limit accessibility in resource-constrained settings and create substantial financial burden on healthcare systems. The development of neutralizing antibodies (inhibitors) in approximately 25-30% of severe hemophilia A patients complicates treatment strategies and increases therapeutic costs. Limited awareness among healthcare providers in developing regions, inadequate cold chain infrastructure for product distribution, and regulatory complexities across different markets pose additional challenges. Supply chain disruptions and plasma shortages for plasma-derived products create market volatility. Nevertheless, substantial opportunities emerge from expanding gene therapy developments, which promise potential functional cures and long-term cost-effectiveness. Growing focus on personalized medicine approaches, telemedicine integration for remote patient monitoring, and increasing healthcare infrastructure investments in Asia Pacific and Latin American markets present significant growth potential for market expansion.

Key Features of the Study

  • This report provides an in-depth analysis of the global coagulation factor deficiency market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global coagulation factor deficiency market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Baxter International Inc., CSL Behring, Grifols S.A., Takeda Pharmaceutical Company, Novo Nordisk A/S, Pfizer Inc., Bayer AG, Sobi (Swedish Orphan Biovitrum), Biogen Inc., Octapharma AG, Sanofi S.A., Amgen Inc., Genentech, Inc., and UCB S.A.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global coagulation factor deficiency market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global coagulation factor deficiency factor.

Market Segmentation

  • Disorder Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Hemophilia A (Factor VIII Deficiency)
    • Hemophilia B (Factor IX Deficiency)
    • Hemophilia C (Factor XI Deficiency)
    • Von Willebrand Disease
    • Type 1-Mild deficiency of von Willebrand factor (VWF)
    • Type 2-Abnormal function of VWF
    • Rare Factor Deficiencies
    • Factor I (Fibrinogen) Deficiency
    • Factor II (Prothrombin) Deficiency
    • Factor V Deficiency
    • Factor VII Deficiency
    • Factor X Deficiency
    • Factor XIII Deficiency
  • Treatment Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Replacement Therapy
    • Plasma-derived Coagulation Factors
    • Recombinant Coagulation Factors
    • Non-replacement Therapy
    • Desmopressin (DDAVP)
    • Antifibrinolytics
    • Anticoagulants
    • Gene Therapy
    • Adeno-Associated Virus (AAV) Gene Therapy
    • Lentivirus Gene Therapy
    • Others (Hormonal Therapy)
  • Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
    • Lyophilized Powder for Reconstitution
    • Liquid Solution for Injection/Infusion
    • Oral Formulations
    • Nasal Spray
    • Other Viral Vector Suspension
  • Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
    • Intravenous
    • Subcutaneous
    • Intranasal
    • Oral
  • Age Group Insights (Revenue, USD Bn, 2020 - 2032)
    • Pediatric
    • Adult
  • End User Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospitals
    • Specialty Pharmacies
    • Hemophilia Treatment Centers
    • Homecare Settings
    • Specialty Clinics
    • Ambulatory Surgical Centers (ASCs)
    • Others (Academic & Research Institutions.)
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Baxter International Inc.
    • CSL Behring
    • Grifols S.A.
    • Takeda Pharmaceutical Company
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Bayer AG
    • Sobi (Swedish Orphan Biovitrum)
    • Biogen Inc.
    • Octapharma AG
    • Sanofi S.A.
    • Amgen Inc.
    • Genentech, Inc.
    • UCB S.A.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Coagulation Factor Deficiency Market, By Disorder Type
    • Global Coagulation Factor Deficiency Market, By Treatment Type
    • Global Coagulation Factor Deficiency Market, By Dosage Form
    • Global Coagulation Factor Deficiency Market, By Route of Administration
    • Global Coagulation Factor Deficiency Market, By Age Group
    • Global Coagulation Factor Deficiency Market, By End User
    • Global Coagulation Factor Deficiency Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Coagulation Factor Deficiency Market, By Disorder Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hemophilia A (Factor VIII Deficiency)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Hemophilia B (Factor IX Deficiency)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Hemophilia C (Factor XI Deficiency)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Von Willebrand Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
      • Type 1-Mild deficiency of von Willebrand factor (VWF)
      • Type 2-Abnormal function of VWF
  • Rare Factor Deficiencies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
      • Factor I (Fibrinogen) Deficiency
      • Factor II (Prothrombin) Deficiency
      • Factor V Deficiency
      • Factor VII Deficiency
      • Factor X Deficiency
      • Factor XIII Deficiency

5. Global Coagulation Factor Deficiency Market, By Treatment Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Replacement Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
      • Plasma-derived Coagulation Factors
      • Recombinant Coagulation Factors
  • Non-replacement Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
      • Desmopressin (DDAVP)
        • Antifibrinolytics
        • Anticoagulants
  • Gene Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
      • Adeno-Associated Virus (AAV) Gene Therapy
      • Lentivirus Gene Therapy
  • Others (Hormonal Therapy)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Coagulation Factor Deficiency Market, By Dosage Form, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Lyophilized Powder for Reconstitution
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Liquid Solution for Injection/Infusion
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Oral Formulations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Nasal Spray
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Other Viral Vector Suspension
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Coagulation Factor Deficiency Market, By Route of Administration, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Subcutaneous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Intranasal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Coagulation Factor Deficiency Market, By Age Group, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Coagulation Factor Deficiency Market, By End User, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Specialty Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Hemophilia Treatment Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Homecare Settings
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Ambulatory Surgical Centers (ASCs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others (Academic & Research Institutions, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Coagulation Factor Deficiency Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

11. Competitive Landscape

  • Baxter International Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • CSL Behring
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Grifols S.A.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novo Nordisk A/S
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sobi (Swedish Orphan Biovitrum)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Biogen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Octapharma AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Genentech, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • UCB S.A.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

12. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

13. References and Research Methodology

  • References
  • Research Methodology
  • About us